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The aim of our longitudinal study was to evaluate bone mass
in girls affected by central precocious puberty (CPP) that
have reached final height, treated with GnRH agonist trip-
torelin (GnRHa), with or without calcium supplementation.
We studied 48 Caucasian females affected by CPP (age at di-
agnosis, 7.19  0.96 yr), randomly assigned to two groups:
group A (n  21) treated with GnRHa and group B (n  27)
treated with GnRHa plus calcium gluconolactate and carbon-
ate (1 g calcium/day in two doses) for at least 2 yr. Auxological
parameters (standing height, weight, body mass index) and
bone mineral density (BMD) at the lumbar spine [L2-L4, an-
teroposterior (AP)-BMD; lateral BMD; volumetric (v)BMD)] by
dual-energy x-ray absorptiometry were evaluated at the be-
ginning [chronological age (CA), 7.29 0.91 yr; bone age (BA),
8.80  1.24 yr] and end of treatment (CA, 11.27  0.97 yr; BA,
12.35  0.43 yr) and at final height (CA, 16.17  1.9 yr; BA,
16.93  0.98 yr, in each case >15 yr). Total bone mineral con-
tent, total BMD, and fat percentage were evaluated at the end
of the study period using dual-energy x-ray absorptiometry.
Final height was significantly higher than predicted height at
diagnosis (159.96.3 cm vs. 152.99.6 cm; P < 0.05). Body mass
index and fat percentage were not statistically different from
control values. Densitometric values at final evaluation in
groups A and B together were lower than in controls, but the
differences were not statistically significant. The vBMD was
significantly higher in group B than in group A at the end of
treatment period (0.213  0.022 g/cm3 vs. 0.192  0.021 g/cm3;
P < 0.01) and at final evaluation (0.246 0.023 g/cm3 vs. 0.227
0.024 g/cm3; P < 0.05). The percentage change (%) between
the start and end of treatment period in AP-BMD and vBMD
was significantly higher in group B than in group A (% AP-
BMD: 20.36%  1.10% vs. 16.16%  1.90%, P < 0.01; % vBMD:
19.08%  3.52% vs. 9.26%  5.15%; P < 0.01) and also between
the start of treatment and final evaluation (% AP-BMD:
61.23%  1.61% vs. 56.97%  1.45%, P < 0.01; % vBMD: 36.69%
 5.01% vs. 28.01%  5.76%, P < 0.01). In all our females with
CPP treated with GnRHa, bone densitometric parameters
were in the normal range for age and sex. However, bone mass
achievement seemed to be better preserved in the group of
patients supplemented with calcium. (J Clin Endocrinol
Metab 88: 1096–1101, 2003)
IT IS WELL KNOWN that bone mineral density (BMD)increases with age and puberty is a crucial period for
bone development and peak bone mass (PBM) achievement
(1). The genetic potential for bone accumulation could be
limited not only by insufficient calcium intake and inade-
quate physical activity but also by disruption of the pubertal
calendar (2). Treatment of precocious puberty with GnRH
agonists (GnRHa) (3), by suppressing gonadotropin secre-
tion and reducing sex steroid levels, may have a detrimental
effect on bone mass during pubertal development (4, 5). On
the other hand, it has been demonstrated that calcium intake
correlates with bone density in healthy children and ado-
lescents (6) and calcium supplementation above the recom-
mended dietary allowances increases bone density in chil-
dren (7, 8).
The aim of the present longitudinal study was to evaluate
bone mass after long-term GnRHa therapy with or without
calcium supplementation in females affected by central pre-
cocious puberty (CPP) who have reached final height to
determine whether GnRHa treatment impaired the achieve-
ment of an adequate bone mass at growth completion and
whether calcium supplementation improved bone mass in
patients treated with GnRHa.
Patients and Methods
Patients
We investigated 48 Caucasian girls affected by CPP. Informed consent
was obtained from the parents of each girl before starting the study
protocol, and local hospital ethical committee approved the study.
Diagnosis of CPP was based on the appearance of pubertal signs
(breast and pubic hair at stage II or above, according to Tanner) before
8 yr of chronological age (CA) (appearance of pubertal signs: CA, 6.94
1.05 yr; age range, 4.5–7.9 yr); bone age (BA) more than 1 yr beyond CA;
uterus longitudinal diameter (detected by ultrasonography) greater than
3.5 cm; LH and FSH responses to the GnRH stimulation test (100 mg/m2,
iv bolus dose); and estradiol concentrations in the pubertal range (9).
None of the patients had evidence of progressive organic disorders
in the central nervous system detected by computed tomography or
magnetic resonance imaging, identifiable adrenal or gonadal pathology,
or thyroid deficiency or had previously been treated with inhibitory
steroids. Renal and hepatic functions were normal.
After CPP diagnosis, patients were assigned to treatment with the
long-acting GnRHa triptorelin (Decapeptyl, IPSEN, Milan, Italy) at a
dose of 3.75 mg, im, every 28 d (0.123  0.12 mg/kg; range 0.10–0.15
Abbreviations: AP-BMD, Anteroposterior bone mineral density; BA,
bone age; BMD, bone mineral density; BMI, body mass index; CA,
chronological age; CPP, central precocious puberty; %, percentage
variation; DXA, dual-energy x-ray absorptiometry; GnRHa, GnRH ag-
onist; L-BMD, lateral BMD; PAH, predicted adult height; PBM, peak
bone mass; % FAT, fat percentage; TBMC, total body bone mineral
content; TBMD, total BMD; TH, target height; vBMD, volumetric BMD.
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mg/kg) for a period of 3.97 1.14 yr (range, 2.1–8.5 yr). CA at diagnosis
was 7.19  0.96 yr; CA and BA at the start of therapy were 7.29  0.91
yr and 8.80  1.24 yr, respectively.
Patients were randomly assigned to two groups (A and B) comparable
for age, BA, height, and weight using a computer pseudorandom num-
ber generator. Patients in group A were treated with GnRHa (n  21)
for a period of 4.08  1.28 yr; patients in group B (n  27) received a
treatment with GnRHa for 3.88  1.31 yr plus supplementation of
calcium gluconolactate and carbonate (1 g calcium/day in two doses)
during GnRHa treatment for a period of 2.89  0.59 yr and in each
case 2 yr (range, 2.1–4.6 yr).
In group A patients, the onset of pubertal signs was at CA of 6.88 
1.21 yr and the CA at diagnosis was of 7.18 1.13 yr. In group B patients,
the onset of pubertal signs was at 6.98 1.12 yr and CA at diagnosis was
7.20  1.09 yr.
No patient received other drugs known to interfere with bone mineral
metabolism. All the subjects were instructed to continue their usual
physical activity and diet, thereby ensuring adequate caloric (70–80
cal/kgd), protein (1 g/kgd), calcium (800 mg/d), and phosphate
(800 mg/d) intake during treatment. Diet and dietary calcium intake
in particular were investigated by a weighed food record and exercise
by an exercise diary. Compliance in assumption of calcium supplemen-
tation was checked by a diary.
The 48 subjects were evaluated at the end of therapy, at CA of 11.27
0.97 yr (range 9.81–12.73) and BA of 12.35  0.43 yr (range 11.5–14 yr)
and with a final evaluation when they reached final height, at CA of
16.17  1.9 yr (range 13.1–21.7 yr) and BA of 16.93  0.98 (in each case
15 yr).
Calcium supplementation was not continued after the stop of GnRHa
treatment. Patients and families of both groups were educated to have
an adequate calcium intake. Mean interval time between stop of treat-
ment and final evaluation was 4.9  1.4 yr for total group of patients
(range 1.6–7.7 yr), 4.7 1.8 yr for group A (range 1.6–7.7 yr), and 5.1
1.6 for group B (range 2.3–6.9 yr). All calcium-supplemented patients
were evaluated at least 2 yr after supplementation was stopped.
During the final evaluation, age at menarche and menstrual pattern
were investigated.
Methods
Standing height, weight, body mass index (BMI), BA, and BMD at the
lumbar spine (L2-L4) were evaluated at the start and end of GnRHa
treatment and at final evaluation. Total body bone mineral content
(TBMC), total BMD (TBMD) and fat percentage (% FAT) were evaluated
at the final evaluation.
Standing height was measured using a Harpenden stadiometer (Hol-
tain Ltd., Crymmyth, UK). BMI was calculated as weight (kilograms)/
height(2) (square meters) and compared with age- and sex-matched
reference values (10) to calculate sd score (SDs). BA evaluation was
determined blindly by the same expert observer according to the Greu-
lich and Pyle method (11) and expressed in years. Predicted adult height
(PAH) at diagnosis, based on height and BA, was calculated by the
Bayley and Pinneau method (12). Target height (TH) was calculated
from the mean height of the parents adjusted for sex, as described by
Tanner et al. (13). Height was considered as final adult stature when BA
was equal to or greater than 15 yr and the patient’s growth rate was less
than 0.5 cm/yr during the preceding year.
TBMC (grams), TBMD (grams per square centimeter), and BMD at the
lumbar spine were measured using dual-energy x-ray absorptiometry
(DXA). BMD at the lumbar spine was assessed at diagnosis and the end
of treatment by Sophos DXA (Sophos L-XRA 3.1, Sopha Medical S.N.I.,
Les Ullis, France). BMD at the lumbar spine, TBMC, and TBMD at the
final evaluation were assessed using DXA (Expert XL; Lunar Corp.,
Madison, WI).
The second, third, and fourth lumbar vertebrae were scanned by
anteroposterior projection (AP-BMD) and lateral scan (L-BMD). DXA-
derived data were used to calculate lumbar spine volumetric BMD
(vBMD), expressed in grams per cubic centimeter, taking the vertebral
body as an ellipsoid cylinder and dividing bone mineral content ob-
tained by lateral scan (in grams) by body vertebral volume (in cubic
centimeters), calculated (width/2depth/2 height) to reduce the
confounding effect of bone size (14). Vertebral dimensions (anterior
width, depth, and height) were obtained using software data. A cross-
calibration between the two DXA lumbar spine instruments was ob-
tained for anteroposterior and lateral scan using morphologic commer-
cial phantom (Hologic, Inc., Waltham, MA). To compare densitometric
data, we applied the conversion factors Sophos-Lunar (Bertoldo, F.,
unpublished data)—AP-BMD: Lunar (estimated)  0.98021 (Sophos)
0.004112; L-BMD: Lunar (estimated)  0.97257 (Sophos) 0.003988;
vBMD: Lunar (estimated)  0.97165 (Sophos) 0.003891.
DXA was calibrated daily using a commercial phantom to exclude
measurement drifts during the study period. Coefficients of variation
were: 1.1% AP-BMD, 1.8% L-BMD, 2.8% vBMD for Sophos instrument
and less than 1% AP-BMD, 1.2% L-BMD, and 2.1% vBMD for Lunar
Corp. instrument, according to the manufacturers. Serial measurements
of phantom were routinely performed during the study. Precision error
for both Sophos and Lunar Corp. instruments was less than 1% during
the study. TBMC, TBMD, and % FAT were measured with Expert XL
(Lunar Corp.). Coefficients of variation were 0.6% for TBMC, 1.0% for
TBMD, 2.2% for fat, according to the manufacturer.
Auxological, body composition, and bone densitometric data were
compared with control groups of the same CA (Tables 1 and 2), with BA
appropriate for CA, BMI between the 25th and 75th percentile (10),
normal intake of calcium and phosphate, and normal physical activity.
The percentage variation (%) in the measured parameters was cal-
culated as: [(measured value  initial value)/initial value]  100.
Statistical analysis
Results are expressed as means  sd. Statistical analyses were per-
formed using unpaired t test, ANOVA, and simple regression analysis.
All statistical analyses were performed using a data analysis system
(StatView 4.5; Abacus Concepts, Inc., Berkeley, CA) run on an Apple
PowerMac computer (Apple Computer, Inc., Cupertino, CA). Statistical
significance was set at P less than 0.05.
Results
Clinical data regarding patients at the start, end of treat-
ment, and final evaluation are reported in Table 1. In all
patients, TH and PAH at the start of treatment were 161.9 
6.3 and 152.9 9.6 cm, respectively. Final height was 159.9
6.2 cm (P  0.05 vs. PAH); it was within TH in 81% of all
patients. Differences between the two groups were not found
(Table 1).
After the stop of treatment, a prompt recovery of hypo-
thalamo-pituitary-gonadal axis activity was seen and the
response to the GnRH stimulation test returned pubertal
after 6–9 months. Menarche or remenarche started at age
12.4  0.9 yr (range 10.9–14.2 yr) in all patients with no
statistical difference between the two groups; no patient
showed pathologic menstrual pattern.
BMI and BMI expressed as sd scores at pretreatment, the
end of treatment, and final evaluation were not significantly
different, with no statistically significant differences among
the two groups and controls (Table 1).
% FAT, determined by DXA, was 30.99%  3.95% for the
total group of patients, 30.75%  4.06% in group A, and
31.18%  3.88% in group B, with no statistical significance
among the two groups and controls (30.51%  5.75%).
There were no differences in exercise levels or exposure to
sunlight between the two groups of subjects, as reported in
each patient’s food and exercise diary. The compliance in
calcium supplementation assumption in group B was more
than 84%. Calcium intake was 897  95 mg/d in group A,
1510  168 mg/d in group B (during the period of calcium
supplementation), and 907 108 mg/d in the control group.
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Table 2 shows DXA evaluation in total group, group A,
group B, and controls
Bone densitometric values (TBMC, TBMD, AP-BMD, L-
BMD, and vBMD) in all patients (groups A and B together)
were lower than in controls, but the differences were not
statistically significant for all parameters studied.
The vBMD levels were significantly higher in group B than
in group A at the end of therapy (0.213  0.022 g/cm3 vs.
0.192  0.021 g/cm3, P  0.01) and final evaluation (0.246 
0.023 g/cm3 vs. 0.227  0.024 g/cm3, P  0.05) (Fig. 1).
The % in AP-BMD and vBMD were significantly higher
in group B than in group A between the beginning and the
end of treatment (% AP-BMD: 20.36%  1.10% vs. 16.16%
 1.90%, P  0.01; % vBMD: 19.08%  3.52% vs. 9.26% 
5.15%, P  0.01) and also between the start of treatment and
final evaluation (% AP-BMD: 61.23% 1.61% vs. 56.97%
1.45%, P  0.01; % vBMD: 36.69%  5.01% vs. 28.01% 
5.76%, P  0.01) (Fig. 2).
Simple regression analysis showed in group B a significant
relationship between duration of calcium supplementation
and % change at final evaluation respect to pretherapy for
AP-BMD (r  0.41, P  0.05) and vBMD (r  0.40, P  0.05)
(Fig. 3).
Discussion
It is well known that BMD increase is age dependent (1)
and about half of the adult PBM is accumulated during
adolescent growth spurt (2) when dietary calcium require-
ments increase substantially (15). In females, the maximum
increase in BMD at lumbar spine occurs between 11 and 14
yr and approaches its peak at age 16–17 yr (16, 17). The
magnitude of PBM achieved during adolescence depends
not only on genetic potential (race, sex, and heredity) (18, 19)
but also on nutritional factors (calcium intake) (20, 21), phys-
ical activity (22, 23), pubertal calendar disruption (2), and
body composition (24).
Regarding body composition, BMI sd score of females
with CPP has been reported to be greater than that of controls
before, during, and after GnRHa therapy (25–27), as in our
patients. However, in our patients, fat mass at final evalu-
ation was not different from that in controls.
GnRHa treatment in patients with CPP is effective in de-
celerating the rates of linear growth and bone maturation,
thus improving significantly final adult height and preserv-
ing genetic height potential (28), as in our patients. On the
other hand, GnRHa treatment, stopping the progression of
pubertal development, and reducing serum estradiol levels
to prepubertal levels leads to a situation of hypoestrogenism,
which may be accompanied by delayed skeletal maturation
FIG. 1. Individual vBMD levels at final evaluation in group A
(GnRHa alone, white circles) and group B (GnRHaCa, black circles).
Control values are represented as an open square (mean)  2 SD.
vBMD levels are significantly higher in group B than in group A
(0.246  0.023 g/cm3 vs. 0.227  0.024 g/cm3, P  0.05).
FIG. 2. The % vBMD in group A (GnRHa alone: white bars) and
group B (GnRHa  Ca: black bars) between the start and stop of
treatment (Start-Stop), stop of treatment and final evaluation (Stop-
Final), and the start of treatment and final evaluation (Start-Final).
The % vBMD was significantly higher in group B than in group A
between the start and stop of treatment (P  0.01) and the start of
treatment and final evaluation (P 0.01). The % was calculated as:
[(measured value  initial value)/initial value]  100.
FIG. 3. Group B patients: simple regression analysis showing signif-
icant relationship between the duration of calcium supplementation
period (years) and % vBMD at final evaluation with respect to
pretherapy (r 0.40, P 0.05). The% was calculated as: [(measured
value  initial value)/initial value]  100.
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and deficient bone mineralization (4, 5, 29). In fact, estrogens
have an important role in promoting normal bone matura-
tion, accruing and maintaining BMD, and controlling bone
turnover rate (30).
In a previous study on girls affected by CPP, we demon-
strated that BMD reduction during GnRHa therapy was re-
versible and preventable by providing calcium supplemen-
tation from the beginning of treatment (31).
In the present cohort of all patients, parameters studied
(final TBMC, TBMD, AP-BMD L2-L4, and vBMD) were in the
normal range, even if lower than in controls, but with no
statistically significant difference. Therefore, GnRHa treat-
ment in our patients with CPP does not seem to impair the
achievement of a normal PBM, as previously reported (26, 32,
33). However, for the first time, we report the PBM at growth
completion in patients treated with GnRHa and calcium. In
these patients vBMD levels at stop of therapy and final eval-
uation were significantly higher than those treated with only
GnRHa. Moreover,% AP-BMD and% vBMD between the
beginning of treatment and final evaluation were also sig-
nificantly higher in calcium-supplemented patients than
those treated with only GnRHa, with a significant relation-
ship with the duration of calcium supplementation.
The study has some limitations. The first is that the
follow-up of bone mass is obtained by two different DXA
machines. Replacement of DXA equipment was necessary in
time as a result of upgrading according with the manufac-
turer. Absolute values of BMD using DXA differ between
instruments; however, in literature, the rates of change cal-
culated from serial measurements on different densitometers
have been assumed to be comparable. Cross-calibration in
general is considered to be the result of linear regression
between the measurements obtained with two densitom-
eters. This method is necessarily used in multicentric studies
(26, 34, 35) or very long longitudinal studies as in our case
(36). The second limitation is that, as well known, PBM is not
achieved at final height but later in life (1). Therefore, the
effect of precocious puberty and its treatment on PBM should
be reevaluated later, at approximately 20–30 yr of age.
It is well known that adolescents often do not have a
sufficient calcium intake (1, 37), and the mean calculated
calcium intake in our noncalcium-supplemented patients
and controls was lower than the recommended dietary al-
lowances. On the contrary, calcium supplementation in pa-
tients of group B permitted to reach an average dietary cal-
cium intake approximating the recommended dietary
allowance and enhanced the rate of BMD increase.
On the other hand, calcium intake above the recom-
mended dietary allowances is positively associated with
bone mass in prepubertal (38, 39) and postpubertal (40, 41)
females. Moreover, calcium supplementation in premenar-
cheal and perimenarcheal period, which appears to be the
best time for bone calcium deposition (15, 42), seems to be
important to reach a higher PBM and avoid the risk of post-
menopausal osteoporosis (1).
Probably the majority of the general population does not
require calcium supplementation because of good genetic
background, adequate diet, and good physical activity. But
in some individuals, such as patients treated with drugs that
potentially interfere with bone mineral metabolism, it is
probably better to increase calcium intake (15, 43).
In conclusion, in our patients with CPP treated with long-
term depot GnRHa, final bone densitometric parameters
were in the normal range for age and sex. In the group of
patients supplemented with calcium, calcium supplementa-
tion is effective in improving bone densitometric levels and
may preserve better PBM achievement.
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